Previous Post: China: Mercury found in baby formula nbsp
Cancer drug’s survivin suppression called into question
Nature – [The protein survivin] was named for its ability to promote cell survival in cancer by blocking programmed cell death—and it’s a protein that has become steadily more familiar in the cancer field in recent years. [Discovered] in 1997, survivin has emerged as one the most commonly found proteins in tumor cells. [It is rare] in healthy tissue, [so] you can understand why several companies have invested heavily in putative antisurvivin agents, with a handful already in clinical testing. The lead compound—YM155 from Japan’s Astellas Pharma—has already completed phase 2 trials for various forms of cancers. However, new data are emerging from preclinical tests to suggest that the drug might not be working exactly as first anticipated. Read article
Tags: genes biotech, nature universe, pharmaceuticals
Views: 0